Pacira Pharma (PCRX) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.35, $0.20 better than the analyst estimate of $0.15. Revenue for the quarter came in at $62.2 million versus the consensus estimate of $60.44 million.
Pacira ended the third quarter of 2015 with cash and cash equivalents, short-term investments and long-term investments (“cash”) of $164.4 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Syra Health Corp. (SYRA) Reports Q3 EPS of $0.02
- Shopify tanks 19% premarket as Q3 GMV, subscription revenue miss estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
